Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if Angiocal® (PRS-050-PEG40) is safe and well
tolerated when it is injected into the veins of patients with solid tumors. Other purposes of
this study are to investigate how the body of the patients reacts to Angiocal®, how the blood
level of Angiocal® develops after injection and how the tumor responds to the injection of
Angiocal®.